Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer
31
0
2023-11-3 17:17
Progressive descending facial nerve paralysis in amyloidosis
Fragile X-associated tremor or ataxia syndrome
Metaphyseal sclerosis in a child with a giant cell tumour treated with denosumab
Always use containment morcellation bags
The Lancet Countdown 2022 - Dr Paula Henry
The Carbon Cost of Healthcare
Efficacy and safety of treating alopecia areata with ritlecitinib
The Lancet | What we publish, and why (BSL-interpreted)
0 bullet chats
Please Sign In first
LikesSend-PenFavorites
Scan by WeChatUnauthorized reproduction is prohibited
Dr James Harding presents the findings of their paper, published in The Lancet Oncology on 2 June 2023: Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZONBTC-01): a multicentre, single-arm, phase 2b study.
Comments 0
Please to post a comment~
Loading...
Related Suggestion